Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

Journal

Citations (1)*help

See more

Details 詳細情報について

  • CRID
    1570009750315603968
  • NII Article ID
    10017475550
  • Data Source
    • CiNii Articles

Report a problem

Back to top